Biotech backs down in 2Q19

Biotech stocks are down across the board in 2Q19 after 1Q19 gains

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in the black with a net gain of $160.7 billion.

Large cap companies valued at $10 billion or more represented the best performing tier of the quarter, losing a median of 1%, and $2.5 billion in market cap.

Leading the group was Hansoh Pharmaceutical Group Co. Ltd., which popped after its Hong Kong IPO in mid-June to close the quarter up 45%, at HK$117.8 billion ($15.1 billion).

Following Hansoh in the large-cap tier was Exact Sciences Inc., which gained 43% in the quarter to a valuation of $15.3 billion. In April, it announced revenues and testing volume for its Cologuard colorectal cancer screening test had increased 79% in 1Q19 over the prior year to $162 million and 334,000 tests. In May, Exact reported data demonstrating 92% sensitivity and specificity for a new pancreatic cancer screening test, and on June 26 it opened a new lab in its hometown of Madison, Wisc. which will allow it to perform up to 7 million tests a year.

At the bottom of the $10 billion-plus group was Teva Pharmaceutical Industries Ltd., which lost 41%, ending the quarter at $10.1 billion. Its share price has been losing steam since a May 11 story in the New York Times said Teva and other drug manufacturers conspired to inflate

Read the full 2448 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE